S100A4 and breast carcinoma: Given our previous findings regarding the inhibition of osteoblast matrix mineralization by recombinant S100A4 treatment [56] and on the elevated secretion of S100A4 from bone-metastatic breast cancer cells [28], we propose that ways to inhibit the function of S100A4 will lead to the prevention of bone loss in osteolytic bone metastases.